PharmAware Blog

The US FDA is looking to investigate a member of the panel that recently recommended restrictions on rosiglitazone for conflict of interest. Dr Capuzzi was one of the panel members who voted to keep rosiglitazone on the market. However, several news organisations have reported that Dr Cauzzi has been a member of GSKs speakers’ bureau.

BMJ 2010; 241:c4083

Danish drug company Novo Nordisk is to withdraw Mixtard30, a form of insulin used by 90,000 patients in the UK. DTB says this will be costly; if all patients switched to Novo Nordisk’s alternative Novomix30, this would cost the NHS £9M a year.

BMJ 2010; 341: c4210